INO

VGX-3100

Precancerous Anal Dysplasia

Phase 2 (Data)

Exp Date

Q4 2020

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: VGX-3100 for Precancerous Anal Dysplasia - Phase 2 Data



WHAT IS THE CATALYST EVENT?

  •  Phase 2 Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA/EVENTS

PRESS RELEASE

MECHANISM OF ACTION

  • VGX-3100 is a DNA medicine under Phase 3 investigation for the treatment of HPV-16 and HPV-18 infection and precancerous lesions of the cervix. INOVIO is in open-label Phase 2 clinical trials evaluating its efficacy for treating HPV-related vulvar and anal dysplasia (HSIL). VGX-3100 has the potential to be the first approved treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions. It works by stimulating a specific immune response to HPV-16 and HPV-18, which targets the infection and causes destruction of precancerous cells. In a randomized, double-blind, placebo-controlled phase 2b study in 167 adult women with histologically documented HPV-16/18 cervical dysplasia (CIN2/3 or HSIL), treatment with VGX-3100 resulted in a statistically significantly greater regression of cervical dysplasia and clearance of HPV-16/18 infection vs. placebo. The most common side effect was injection site pain, and no serious adverse events were reported. VGX-3100 utilizes the patient's own immune system to clear HPV-16 and HPV-18 infection and precancerous lesions without the increased risks associated with surgery, such as loss of reproductive health and negative psychosocial impacts.

Updated by HC

INO, Precancerous Anal Dysplasia, VGX-3100 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon